How many insider trades does FilingIQ track for JANX?

FilingIQ tracks 244 Form 4 insider transactions for JANX (Janux Therapeutics, Inc.), covering filings from Jun 15, 2021 onwards. 1 of those were filed in the last 90 days.

Are JANX insiders net buyers or net sellers?

Across the full Form 4 history for JANX, 19 transactions (8%) were open-market purchases and 102 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does JANX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is JANX in?

Janux Therapeutics, Inc. (JANX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $791.24M.

JANX insider trading

Healthcare

Janux Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

244

Last 90 days

Buys / sells

8% / 42%

Market cap

$791.24M

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Janux Therapeutics, Inc. has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. The company was incorporated in 2017 and is headquartered in San Diego, California.

Company website: www.januxrx.com

JANX insider activity at a glance

FilingIQ has scored 244 insider transactions for JANX since Jun 15, 2021. The most recent filing in our index is dated May 11, 2026.

Across the full history, 19 open-market purchases and 102 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on JANX insider trades is 56.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live JANX trades on FilingIQ Raw filings on SEC EDGAR

Latest JANX Form 4 filings

Campbell David Alan President and CEO

S Dec 24, 2024

Reardon Tighe Acting Chief Financial Officer

P Nov 13, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding JANX

Logos Global Management LP

$31.42M · 2.5% of AUM

Samsara BioCapital, LLC

$4.36M · 0.9% of AUM

Frequently asked

How many insider trades does FilingIQ track for JANX?: FilingIQ tracks 244 Form 4 insider transactions for JANX (Janux Therapeutics, Inc.), covering filings from Jun 15, 2021 onwards. 1 of those were filed in the last 90 days.
Are JANX insiders net buyers or net sellers?: Across the full Form 4 history for JANX, 19 transactions (8%) were open-market purchases and 102 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does JANX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is JANX in?: Janux Therapeutics, Inc. (JANX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $791.24M.

Methodology & sources

Every JANX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.